EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx ® (secukinumab) in adults with newly diagnosed or ...
(RTTNews) - Novartis reported top-line results from the Phase III GCAptAIN study evaluating Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis. The company said Cosentyx did not ...
Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results